-
Sanofi Secures Rights to Graviton’s ROCK2 Inhibitor Candidates in Strategic Biotechnology Investment
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has made an undisclosed investment in biotechnology firm Graviton Bioscience, securing a right of first negotiation for Graviton’s clinical-stage ROCK2 inhibitor candidates in immunological and metabolic syndrome indications. Graviton’s lead program, GV101, is a potential best-in-class ROCK2 inhibitor capable of crossing the…
-
NHSA Launches Service Specifications for Medical Procurement Platform
•
The National Healthcare Security Administration (NHSA) has issued the “Service Specification for Medical Centralized Procurement Platform (Version 1.0)”, which came into effect on July 1, 2024. This document, known as the “Regulations”, concentrates on service aspects of the centralized procurement platform, detailing procedures that include enterprise applications, information authentication standards,…
-
China’s NHC Unveils 2024 Goals for Medical Quality and Safety Improvement
•
The National Health Commission (NHC) has released the “2024 National Medical Quality and Safety Improvement Goals,” along with quality control work improvement goals for various medical specialties. These goals aim to enhance management standards related to medical quality and safety. The 10 goals outlined by the NHC include improving the…
-
WuXi Biologics Achieves Full-Scale Manufacturing Milestone at Ireland Facility
•
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has announced the successful completion of the inaugural manufacturing batch at its state-of-the-art drug substance facility, MFG7, located in Ireland. This milestone marks a significant step towards facilitating large-scale commercial manufacturing projects at the…
-
HitGen Inc. and Bostal Drug Delivery Form Strategic Partnership to Advance Nucleic Acid Drug Development
•
HitGen Inc. (SHA: 688222), a China-based company, has announced a strategic partnership with Bostal Drug Delivery Co., Ltd through its subsidiary, Sichuan Xiandong Pharmaceutical Co., Ltd. This alliance is aimed at the research and development (R&D) and manufacturing of nucleic acid drugs, marking a significant step forward in the field…
-
Novartis and Fudan University Shanghai Cancer Center Renew Partnership to Drive Precision Cancer Treatments
•
Novartis (NYSE: NVS), the Swiss pharmaceutical colossus, has renewed its memorandum of understanding with Fudan University Shanghai Cancer Center, signaling a continuation of their strategic partnership. The two entities have committed to an extensive collaboration in scientific research, platform development, and other key areas, with a particular focus on advancing…
-
Rebecca Tech Secures USD 10 Million in Series A++ Funding to Expand Micro RF Technology Globally
•
Rebecca Tech LLC, a Hangzhou-based manufacturer specializing in microelectromechanical RF (radiofrequency) technology, has announced the successful closure of a Series A++ financing round worth USD 10 million. The round was led by Med-Fine Capital, with participation from Puhua Leading Investment. The funds raised will be allocated towards the global promotion…
-
Jiangsu Hengrui Receives Chinese Approval for First Domestic Category 1 Opioid Analgesic for Postoperative Pain
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has proclaimed the receipt of marketing approval in China for its proprietary drug, tegileridine, indicated for the management of moderate to severe pain following abdominal surgery. This milestone marks the drug as the nation’s inaugural Category 1 opioid analgesic developed indigenously, highlighting a…
